• Please log in or register to access this feature.
You have free access to this content

BSACI guidelines for the management of chronic urticaria and angio-oedema

  1. R. J. Powell1,
  2. G. L. Du Toit2,
  3. N. Siddique3,
  4. S. C. Leech4,
  5. T. A. Dixon5,
  6. A. T. Clark6,
  7. R. Mirakian6,
  8. S. M. Walker7,
  9. P. A. J. Huber8,
  10. S. M. Nasser6

Article first published online: 22 MAR 2007

DOI: 10.1111/j.1365-2222.2007.02678.x

Issue

Clinical & Experimental Allergy

Clinical & Experimental Allergy

Volume 37, Issue 5, pages 631–650, May 2007

Additional Information

How to Cite

Powell, R. J., Du Toit, G. L., Siddique, N., Leech, S. C., Dixon, T. A., Clark, A. T., Mirakian, R., Walker, S. M., Huber, P. A. J. and Nasser, S. M. (2007), BSACI guidelines for the management of chronic urticaria and angio-oedema. Clinical & Experimental Allergy, 37: 631–650. doi: 10.1111/j.1365-2222.2007.02678.x

Author Information

  1. 1

    Clinical Immunology Unit, Queen's Medical Centre, Nottingham, UK

  2. 2

    Evelina Children's Hospital, Guys & St Thomas' Trust, Kings College London, London, UK

  3. 3

    The David Hide Asthma & Allergy Research Centre, St Mary's Hospital Newport, UK

  4. 4

    Department of Child Health, Kings College Hospital, Denmark Hill, London, UK

  5. 5

    Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool, UK

  6. 6

    Allergy Clinic, Addenbrooke's Hospital, Cambridge, UK

  7. 7

    Education for Health, The Athenaeum, UK

  8. 8

    British Society for Allergy and Clinical Immunology, London, UK

*Correspondence: Dr S. M. Nasser, Allergy Clinic, Addenbrooke's Hospital Box 40, Clinic 2A, Cambridge CB2 2QQ UK. E-mail: shuaib.nasser@addenbrookes.nhs.uk

Publication History

  1. Issue published online: 22 MAR 2007
  2. Article first published online: 22 MAR 2007
  3. Submitted 31 August 2006; revised 4 January 2007; accepted 8 January 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (213K)

References

  • 1
    Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003; 3:363–8.
  • 2
    Gaig P, Olona M, Munoz LD et al. Epidemiology of urticaria in Spain. J Invest Allergol Clin Immunol 2004; 14:214–20.
  • 3
    O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197–201.
  • 4
    Baiardini I, Giardini A, Pasquali M et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58:621–3.
    Direct Link:
  • 5
    Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64:2515–36.
  • 6
    Sabroe RA, Fiebiger E, Francis DM et al. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 2002; 110:492–9.
  • 7
    Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002; 346:175–9.
  • 8
    Vazquez NF, Meida Arvizu VM, Sanchez Nuncio HR, Villanueva Carreto ML, Guidos FogelbachGA. Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico. Rev Alerg Mex 2004; 51:181–8.
  • 9
    Sabroe RA, Seed PT, Francis DM, Barr RM, Black AK, Greaves MW. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999; 40:443–50.
  • 10
    Oliver MG, Specian RD, Perry MA, Granger DN. Morphologic assessment of leukocyte-endothelial cell interactions in mesenteric venules subjected to ischemia and reperfusion. Inflammation 1991; 15:331–46.
  • 11
    Ley K. Integration of inflammatory signals by rolling neutrophils. Immunol Rev 2002; 186:8–18.
    Direct Link:
  • 12
    Du Toit G, Prescott R, Lawrence P et al. Autoantibodies to the high-affinity IgE receptor in children with chronic urticaria. Ann Allergy Asthma Immunol 2006; 96:341–4.
  • 13
    Brunetti L, Francavilla R, Miniello VL et al. High prevalence of autoimmune urticaria in children with chronic urticaria. J Allergy Clin Immunol 2004; 114:922–7.
  • 14
    Asero R, Tedeschi A, Lorini M, Salimbeni R, Zanoletti T, Miadonna A. Chronic urticaria: novel clinical and serological aspects. Clin Exp Allergy 2001; 31:1105–10.
  • 15
    Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999; 104:169–72.
  • 16
    Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84:66–71.
  • 17
    Leznoff A, Josse RG, Denburg J, Dolovich J. Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 1983; 119:636–40.
  • 18
    Rumbyrt JS, Katz JL, Schocket AL. Resolution of chronic urticaria in patients with thyroid autoimmunity. J Allergy Clin Immunol 1995; 96:901–5.
  • 19
    Kikuchi Y, Fann T, Kaplan AP. Antithyroid antibodies in chronic urticaria and angioedema. J Allergy Clin Immunol 2003; 112:218.
  • 20
    Reichel M, Mauro TM. Urticaria and hepatitis C. Lancet 1990; 336:822–3.
  • 21
    Kanazawa K, Yaoita H, Tsuda F, Okamoto H. Hepatitis C virus infection in patients with urticaria. J Am Acad Dermatol 1996; 35:195–8.
  • 22
    Siddique N, Pereira BN, Hasan AS. Hepatitis C and urticaria: cause and effect? Allergy 2004; 59:668.
  • 23
    Vaida GA, Goldman MA, Bloch KJ. Testing for hepatitis B virus in patients with chronic urticaria and angioedema. J Allergy Clin Immunol 1983; 72:193–8.
  • 24
    Black AK, Lawlor F, Greaves MW. Consensus meeting on the definition of physical urticarias and urticarial vasculitis. Clin Exp Dermatol 1996; 21:424–6.
    Direct Link:
  • 25
    Kushimoto H, Aoki T. Masked type I wheat allergy. Relation to exercise-induced anaphylaxis. Arch Dermatol 1985; 121:355–60.
  • 26
    Papadopoulou N, Kalogeromitros D, Staurianeas NG, Tiblalexi D, Theoharides TC. Corticotropin-releasing hormone receptor-1 and histidine decarboxylase expression in chronic urticaria. J Invest Dermatol 2005; 125:952–5.
  • 27
    Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114:465–74.
  • 28
    Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001; 24:599–606.
  • 29
    Lee A. Adverse drug reactions, 2nd Edn. London Pharmaceutical Press, London and Chicago, 2006.
  • 30
    Kaplan AP. C1 inhibitor deficiency: hereditary and acquired forms. J Invest Allergol Clin Immunol 2001; 11:211–9.
  • 31
    Vleeming W, Van Amsterdam JG, Stricker BH, De Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf 1998; 18:171–88.
  • 32
    Kostis JB, Kim HJ, Rusnak J et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165:1637–42.
  • 33
    Guo X, Dick L. Late onset angiotensin-converting enzyme induced angioedema: case report and review of the literature. J Okla State Med Assoc 1999; 92:71–73.
  • 34
    Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004; 164:910–3.
  • 35
    Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 2001; 46:1239–43.
  • 36
    Pavletic AJ. Late angio-oedema in patients taking angiotensin-converting-enzyme inhibitors. Lancet 2002; 360:493–4.
  • 37
    Warrier MR, Copilevitz CA, Dykewicz MS, Slavin RG. Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. Ann Allergy Asthma Immunol 2004; 92:573–5.
  • 38
    Karim MY, Masood A. Fresh-frozen plasma as a treatment for life-threatening ACE-inhibitor angioedema. J Allergy Clin Immunol 2002; 109:370–1.
  • 39
    Gompels MM, Lock RJ, Abinun M et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139:379–94.
  • 40
    Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998; 138:635–8.
    Direct Link:
  • 41
    Champion RH. Urticaria: then and now. Br J Dermatol 1988; 119:427–36.
  • 42
    Toubi E, Kessel A, Avshovich N et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004; 59:869–73.
  • 43
    Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol 1998; 134:1575–80.
  • 44
    Ewan PW. Clinical study of peanut and nut allergy in 62 consecutive patients: new features and associations. BMJ 1996; 312:1074–8.
  • 45
    Chong SU, Worm M, Zuberbier T. Role of adverse reactions to food in urticaria and exercise-induced anaphylaxis. Int Arch Allergy Immunol 2002; 129:19–26.
  • 46
    Dohi M, Suko M, Sugiyama H et al. Food-dependent, exercise-induced anaphylaxis: a study on 11 Japanese cases. J Allergy Clin Immunol 1991; 87:34–40.
  • 47
    Sabroe RA, Grattan CE, Francis DM, Barr RM, Kobza BA, Greaves MW. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140:446–52.
  • 48
    Zuberbier T, Munzberger C, Haustein U et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology 1996; 193:324–7.
  • 49
    Zuberbier T, Ifflander J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol 1996; 76:295–7.
  • 50
    Pollack CV Jr, Romano TJ. Outpatient management of acute urticaria: the role of prednisone. Ann Emerg Med 1995; 26:547–51.
  • 51
    Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32:489–98.
  • 52
    Simons FE. Advances in H1-antihistamines. N Engl J Med 2004; 351:2203–17.
  • 53
    Monroe EW, Fox RW, Green AW et al. Efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticaria. J Am Acad Dermatol 1988; 19:138–9.
  • 54
    Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40:72–6.
  • 55
    Di Lorenzo G, Pacor ML, Mansueto P et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol 2004; 114:619–25.
  • 56
    Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 104:1071–8.
  • 57
    Juhlin L, Arendt C. Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. Br J Dermatol 1988; 119:67–71.
    Direct Link:
  • 58
    Goh CL, Wong WK, Lim J. Cetirizine vs placebo in chronic idiopathic urticaria – a double blind randomised cross-over study. Ann Acad Med Singapore 1991; 20:328–30.
  • 59
    Schroter S, Damveld B, Marsch WC. Urticarial intolerance reaction to cetirizine. Clin Exp Dermatol 2002; 27:185–7.
    Direct Link:
  • 60
    Tella R, Gaig P, Bartra J, Garcia-Ortega P. Urticaria to cetirizine. J Invest Allergol Clin Immunol 2002; 12:136–7.
  • 61
    Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2005; 54:469–74.
  • 62
    Van Joost T, Blog FB, Westerhof W et al. A comparison of acrivastine versus terfenadine and placebo in the treatment of chronic idiopathic urticaria. J Int Med Res 1989; 17 (Suppl. 2):14B–7B.
  • 63
    Hindmarch I, Johnson S, Meadows R, Kirkpatrick T, Shamsi Z. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001; 17:241–55.
  • 64
    Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat 2004; 15:55–7.
  • 65
    Curran MP, Scott LJ, Perry CM. Cetirizine: a review of its use in allergic disorders. Drugs 2004; 64:523–61.
  • 66
    Verster JC, Volkerts ER, Van Oosterwijck AW et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003; 111:623–7.
  • 67
    Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004; 113:134–40.
  • 68
    Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001; 31:1607–14.
    Direct Link:
  • 69
    Perez C, Sanchez-Borges M, Capriles E. Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema. J Allergy Clin Immunol 2001; 108:1060–1.
  • 70
    Reimers A, Pichler C, Helbling A, Pichler WJ, Yawalkar N. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002; 32:1763–8.
    Direct Link:
  • 71
    Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res 2005; 297:134–8.
  • 72
    White M, Rothrock S, Meeves S, Liao Y, Georges G. Comparative effects of fexofenadine and montelukast on allergen-induced wheal and flare. Allergy Asthma Proc 2005; 26:221–8.
  • 73
    Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34:1401–7.
  • 74
    Nettis E, Pannofino A, Cavallo E, Ferrannini A, Tursi A. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol 2003; 112:212–3.
  • 75
    Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002; 110:484–8.
  • 76
    Nettis E, Dambra P, D'Oronzio L, Loria MP, Ferrannini A, Tursi A. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol 2001; 137:99–100.
  • 77
    Grattan CE, O'Donnell BF, Francis DM et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 2000; 143:365–72.
    Direct Link:
  • 78
    Baskan EB, Tunali S, Turker T, Saricaoglu H. Comparison of short- and long-term cyclosporine A therapy in chronic idiopathic urticaria. J Dermatolog Treat 2004; 15:164–8.
  • 79
    Di Gioacchino M, Di Stefano F, Cavallucci E et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc 2003; 24:285–90.
  • 80
    Kessel A, Bamberger E, Toubi E. Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study. J Am Acad Dermatol 2005; 52:145–8.
  • 81
    Cicardi M, Bergamaschini L, Zingale LC, Gioffre D, Agostoni A. Idiopathic nonhistaminergic angioedema. Am J Med 1999; 106:650–4.
  • 82
    Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. Acta Derm Venereol 1977; 57:369–70.
  • 83
    Monroe EW, Cohen SH, Kalbfleisch J, Schulz CI. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol 1981; 117:404–7.
  • 84
    Paul E, Bodeker RH. Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients. Eur J Clin Pharmacol 1986; 31:277–80.
  • 85
    Bleehen SS, Thomas SE, Greaves MW et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol 1987; 117:81–8.
  • 86
    Black AK, Greaves MW. Antihistamines in urticaria and angioedema. Clin Allergy Immunol 2002; 17:249–86.
  • 87
    Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999; 318:593–6.
  • 88
    British Thoracic Society (BTS) British guideline on the management of asthma. Thorax 2003; 58 (Suppl. 1):i1–94.
  • 89
    Bressler RB, Sowell K, Huston DP. Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial. J Allergy Clin Immunol 1989; 83:756–63.
  • 90
    Asherson RA, Buchanan N, Kenwright S, Fletcher CM, Hughes GR. The normocomplementemic urticarial vasculitis syndrome-report of a case and response to colchicine. Clin Exp Dermatol 1991; 16:424–7.
    Direct Link:
  • 91
    Engler RJ, Squire E, Benson P. Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Ann Allergy Asthma Immunol 1995; 74:155–9.
  • 92
    Jaffer AM. Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria. J Allergy Clin Immunol 1991; 88:964–5.
  • 93
    Eiser AR, Singh P, Shanies HM. Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis – a case report. Angiology 1997; 48:1019–22.
  • 94
    Gonzalez P, Soriano V, Caballero T, Niveiro E. Idiopatic angioedema treated with dapsone. Allergol Immunopathol (Madrid) 2005; 33:54–6.
  • 95
    Gach JE, Sabroe RA, Greaves MW, Black AK. Methotrexate-responsive chronic idiopathic urticaria: a report of two cases. Br J Dermatol 2001; 145:340–3.
  • 96
    Stack PS. Methotrexate for urticarial vasculitis. Ann Allergy 1994; 72:36–8.
  • 97
    Parsad D, Pandhi R, Juneja A. Stanozolol in chronic urticaria: a double blind, placebo controlled trial. J Dermatol 2001; 28:299–302.
  • 98
    Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30:1161–5.
    Direct Link:
  • 99
    Aversano M, Caiazzo P, Iorio G, Ponticiello L, Lagana B, Leccese F. Improvement of chronic idiopathic urticaria with L-thyroxin: a new TSH role in immune response? Allergy 2005; 60:489–93.
  • 100
    Gaig P, Garcia-Ortega P, Enrique E, Richart C. Successful treatment of chronic idiopathic urticaria associated with thyroid autoimmunity. J Invest Allergol Clin Immunol 2000; 10:342–5.
  • 101
    Reeves GE, Boyle MJ, Bonfield J, Dobson P, Loewenthal M. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 2004; 34:182–6.
  • 102
    Minciullo PL, Saija A, Bonanno D, Ferlazzo E, Gangemi S. Montelukast-induced generalized urticaria. Ann Pharmacother 2004; 38:999–1001.
  • 103
    O'Donnell BF, Barr RM, Black AK et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998; 138:101–6.
    Direct Link:
  • 104
    Grattan C, Powell S, Humphreys F. Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 2001; 144:708–14.
    Direct Link:
  • 105
    Nettis E, Colanardi MC, Ferrannini A, Tursi A. Suspected tartrazine-induced acute urticaria/angioedema is only rarely reproducible by oral rechallenge. Clin Exp Allergy 2003; 33:1725–9.
    Direct Link:
  • 106
    Dean T. Deputy director to the David Hide Asthma and Allergy Research Centre, 2005, Personal Communication.
  • 107
    Volonakis M, Katsarou-Katsari A, Stratigos J. Etiologic factors in childhood chronic urticaria. Ann Allergy 1992; 69: 61–5.
  • 108
    Levy Y, Segal N, Weintrob N, Danon YL. Chronic urticaria: association with thyroid autoimmunity. Arch Dis Child 2003; 88:517–9.
  • 109
    Zauli D, Grassi A, Granito A et al. Prevalence of silent coeliac disease in atopics. Dig Liver Dis 2000; 32:775–9.
  • 110
    Gabrielli M, Candelli M, Cremonini F et al. Idiopathic chronic urticaria and celiac disease. Dig Dis Sci 2005; 50:1702–4.
  • 111
    Caminiti L, Passalacqua G, Magazzu G et al. Chronic urticaria and associated coeliac disease in children: a case-control study. Pediatr Allergy Immunol 2005; 16:428–32.
  • 112
    Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2000; 85:521–44.
  • 113
    Greaves MW. Chronic urticaria in childhood. Allergy 2000; 55:309–20.
    Direct Link:
  • 114
    Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA, USA: Littleton Publishing Sciences Group, 1977.
  • 115
    Aselton P, Jick H, Milunsky A, Hunter JR, Stergachis A. First-trimester drug use and congenital disorders. Obstet Gynecol 1985; 65:451–5.
  • 116
    Jick H, Holmes LB, Hunter JR, Madsen S, Stergachis A. First-trimester drug use and congenital disorders. JAMA 1981; 246:343–6.
  • 117
    Kallen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002; 11:146–52.
  • 118
    Diav-Citrin O, Shechtman S, Aharonovich A et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003; 111:1239–43.
  • 119
    Einarson A, Bailey B, Jung G, Spizzirri D, Baillie M, Koren G. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997; 78:183–6.
  • 120
    Hilbert J, Radwanski E, Affrime MB et al. Excretion of loratadine in human breast milk. J Clin Pharmacol 1988; 28:234–9.
  • 121
    Briggs GB, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 6th Edn., Hagerstown, MD, USA: Lippincott Williams & Wilkins, 2001.
View Full Article (HTML) Get PDF (213K)